Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Brought to you by

Baxter, Kuros Biosurgery in tissue repair deal; then Kuros regains rights to most candidates

Dec 2005

Executive Summary

Baxter's biosurgery business is entering the orthobiologics market. It has licensed exclusive worldwide rights to develop and market a portfolio of bone and soft tissue repair products that will use the company's Tisseel fibrin biomatrix in combination with biologic agents and related binding technology that were invented by Kuros Biosurgery AG.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By